From pH to MALDI-TOF

Hundreds of spotted opportunities?

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Current protocols for quality assurance of platelet concentrates used in transfusion therapy include evaluation of platelet count and pH, in vitro measurements of platelet lysis, membrane activation and microparticle release and assays of platelet ability to respond to aggregation stimuli and to hypotonic shock. Unfortunately, these assays show limited correlation to post-transfusion platelet survival and recovery in the recipient. This requires validation of platelet collection and storage systems with expensive and time consuming autologous transfusion studies in healthy volunteers with radiolabeled platelets. Furthermore, platelets from some donors show increased lesion during storage for reasons that are incompletely understood. This editorial discusses recent strides in proteomic technology which open interesting perspectives for improving current procedures for quality assurance of platelet concentrates and increasing the safety and effectiveness of platelet transfusion in medical and surgical conditions. This article is part of a Special Issue entitled: Integrated omics.

Original languageEnglish
Pages (from-to)270-274
Number of pages5
JournalJournal of Proteomics
Volume76
DOIs
Publication statusPublished - Dec 5 2012

Fingerprint

Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Platelets
Blood Platelets
Platelet Transfusion
Quality assurance
Assays
Osmotic Pressure
Platelet Count
Proteomics
Healthy Volunteers
Tissue Donors
Technology
Safety
Membranes
Agglomeration
Chemical activation
Recovery

Keywords

  • Apheresis
  • Platelet concentrate
  • Platelet transfusion
  • Quality assurance

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics

Cite this

From pH to MALDI-TOF : Hundreds of spotted opportunities? / Rebulla, Paolo.

In: Journal of Proteomics, Vol. 76, 05.12.2012, p. 270-274.

Research output: Contribution to journalArticle

@article{e222928f8e6b4700a3e947912ae359d9,
title = "From pH to MALDI-TOF: Hundreds of spotted opportunities?",
abstract = "Current protocols for quality assurance of platelet concentrates used in transfusion therapy include evaluation of platelet count and pH, in vitro measurements of platelet lysis, membrane activation and microparticle release and assays of platelet ability to respond to aggregation stimuli and to hypotonic shock. Unfortunately, these assays show limited correlation to post-transfusion platelet survival and recovery in the recipient. This requires validation of platelet collection and storage systems with expensive and time consuming autologous transfusion studies in healthy volunteers with radiolabeled platelets. Furthermore, platelets from some donors show increased lesion during storage for reasons that are incompletely understood. This editorial discusses recent strides in proteomic technology which open interesting perspectives for improving current procedures for quality assurance of platelet concentrates and increasing the safety and effectiveness of platelet transfusion in medical and surgical conditions. This article is part of a Special Issue entitled: Integrated omics.",
keywords = "Apheresis, Platelet concentrate, Platelet transfusion, Quality assurance",
author = "Paolo Rebulla",
year = "2012",
month = "12",
day = "5",
doi = "10.1016/j.jprot.2012.07.044",
language = "English",
volume = "76",
pages = "270--274",
journal = "Journal of Proteomics",
issn = "1874-3919",
publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - From pH to MALDI-TOF

T2 - Hundreds of spotted opportunities?

AU - Rebulla, Paolo

PY - 2012/12/5

Y1 - 2012/12/5

N2 - Current protocols for quality assurance of platelet concentrates used in transfusion therapy include evaluation of platelet count and pH, in vitro measurements of platelet lysis, membrane activation and microparticle release and assays of platelet ability to respond to aggregation stimuli and to hypotonic shock. Unfortunately, these assays show limited correlation to post-transfusion platelet survival and recovery in the recipient. This requires validation of platelet collection and storage systems with expensive and time consuming autologous transfusion studies in healthy volunteers with radiolabeled platelets. Furthermore, platelets from some donors show increased lesion during storage for reasons that are incompletely understood. This editorial discusses recent strides in proteomic technology which open interesting perspectives for improving current procedures for quality assurance of platelet concentrates and increasing the safety and effectiveness of platelet transfusion in medical and surgical conditions. This article is part of a Special Issue entitled: Integrated omics.

AB - Current protocols for quality assurance of platelet concentrates used in transfusion therapy include evaluation of platelet count and pH, in vitro measurements of platelet lysis, membrane activation and microparticle release and assays of platelet ability to respond to aggregation stimuli and to hypotonic shock. Unfortunately, these assays show limited correlation to post-transfusion platelet survival and recovery in the recipient. This requires validation of platelet collection and storage systems with expensive and time consuming autologous transfusion studies in healthy volunteers with radiolabeled platelets. Furthermore, platelets from some donors show increased lesion during storage for reasons that are incompletely understood. This editorial discusses recent strides in proteomic technology which open interesting perspectives for improving current procedures for quality assurance of platelet concentrates and increasing the safety and effectiveness of platelet transfusion in medical and surgical conditions. This article is part of a Special Issue entitled: Integrated omics.

KW - Apheresis

KW - Platelet concentrate

KW - Platelet transfusion

KW - Quality assurance

UR - http://www.scopus.com/inward/record.url?scp=84869878244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869878244&partnerID=8YFLogxK

U2 - 10.1016/j.jprot.2012.07.044

DO - 10.1016/j.jprot.2012.07.044

M3 - Article

VL - 76

SP - 270

EP - 274

JO - Journal of Proteomics

JF - Journal of Proteomics

SN - 1874-3919

ER -